THU0262 Comparing Abatacept to Adalimumab, Etanercept and Infliximab as First or Second Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry

I. Fortin; D. Choquette; L. Bessette; B. Haraoui; J.-P. Pelletier; J.-P. Raynauld; M.-A. Rémillard; D. Sauvageau; Έ. Villeneuve; L. Coupal

doi:10.1136/annrheumdis-2014-eular.1885

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

EULAR 2014: Scientific Abstracts

Poster Presentations. Rheumatoid arthritis - prognosis, predictors and outcome

THU0262 Comparing Abatacept to Adalimumab, Etanercept and Infliximab as First or Second Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry

Main menu

Online download statistics by month:

Online download statistics by month:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month:

Read the full text or download the PDF:

Log in using your username and password